Glenmark posts Q2 results, sees growth from US, Indian and Russian markets
Net profit for Q2 was Rs 1567.52million as compared to Rs 782.75 million for the previous quarter
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
DRL records YoY growth of 27 per cent in Q2 FY13
Revenues from the global generics segment primarily driven by North America, India and other emerging markets
Piramal Enterprises’ Healthcare in alliance with Fujifilm Diosynth Biotechnologies
Will offer the seamless contract development and manufacture of antibody drug conjugates
Venus Remedies bags first Mexican patent for research product
The patent is valid till February 2026
Partnership for TB Care and Control in India invites application for TB Champion AWARD
Award to be given in individual and organisation category
FDA works with partners to establish important therapeutic area data standards
Will bring together clinical data experts from the FDA, the pharma industry, and the information technology sector, to develop and…
Lonza and OncoMed Pharmaceuticals sign agreement for anti-cancer therapeutics
Contract covers the process development and production of OncoMed’s monoclonal antibody portfolio targeting the biological…
RCC partners with ViruSure
To offer Biosafety Testing Expertise for India´s biopharmaceutical companies